成人特应性湿疹或银屑病患者中与抑郁、焦虑及严重精神疾病相关的因素:系统综述与荟萃分析
该系统综述与荟萃分析检索至2022年2月的文献,纳入21项研究(11项观察性研究、10项随机对照试验),评估成人特应性湿疹(AE)或银屑病患者中与抑郁、焦虑及严重精神疾病(SMI)相关的因素。在银屑病人群中,荟萃分析提示女性与银屑病关节炎与抑郁和焦虑相关,中重度银屑病与焦虑相关但与抑郁无关;随机对照试验证据提示安慰剂组抑郁和焦虑评分高于靶向治疗组,但随访有限。
要点
- 女性与银屑病关节炎与银屑病患者的抑郁和焦虑相关(荟萃分析)。
- 中重度银屑病与焦虑相关(OR 1.14),但与抑郁无显著关联。
- 随机对照试验提示安慰剂组抑郁和焦虑评分高于靶向治疗组,但随访有限。
核心结论
- 本综述强调关于成人AE或银屑病患者中与抑郁、焦虑及SMI相关因素的研究有限。
- 银屑病患者中与抑郁或焦虑相关因素的观察性证据存在冲突或来自单一研究,但部分因素与一般人群一致。
- AE或银屑病患者中与SMI相关因素的证据尤其有限。
- 随机对照试验证据提示,与靶向治疗相比,安慰剂治疗的AE和银屑病与更高的抑郁和焦虑评分相关,但随访有限,因此对心理健康的长期影响尚不清楚。
研究设计与样本
- 检索电子数据库、灰色文献数据库和临床试验注册库,从建库至2022年2月,无语言或地域限制。
- 纳入报告与抑郁、焦虑或SMI相关因素效应估计的随机对照试验、队列研究、横断面研究或病例对照研究。
- 使用预后研究质量工具评估偏倚风险。
- 叙事性合成结果;若至少两项研究足够同质,则采用随机效应荟萃分析合并效应估计。
- 共纳入21项研究(11项观察性研究,10项随机对照试验);AE的观察性研究无一项符合纳入标准。
主要发现
- 银屑病患者的观察性研究主要探讨与抑郁或焦虑相关的因素;一项横断面研究探讨了与精神分裂症相关的因素。
- 女性与抑郁相关(OR 1.62,95%CI 1.09-2.40,95%预测区间0.62-4.23,I²=24.90%,τ²=0.05),与焦虑相关(OR 2.59,95%CI 1.32-5.07,95%预测区间0.00-3956.27,I²=61.90%,τ²=0.22)。
- 银屑病关节炎与抑郁相关(OR 2.26,95%CI 1.56-3.25,95%预测区间0.21-24.23,I²=0.00%,τ²=0.00),与焦虑相关(OR 1.98,95%CI 1.33-2.94,I²=0.00%,τ²=0.00)。
- 中重度银屑病与焦虑相关(OR 1.14,95%CI 1.05-1.25,I²=0.00%,τ²=0.00),但与抑郁无显著关联。
- 随机对照试验证据提示,接受安慰剂的AE或银屑病成人抑郁和焦虑评分高于接受靶向治疗(如生物制剂)的对照者。
关键数值与推荐
- 女性:抑郁OR 1.62(95%CI 1.09-2.40),焦虑OR 2.59(95%CI 1.32-5.07)。
- 银屑病关节炎:抑郁OR 2.26(95%CI 1.56-3.25),焦虑OR 1.98(95%CI 1.33-2.94)。
- 中重度银屑病:焦虑OR 1.14(95%CI 1.05-1.25),与抑郁无显著关联。
临床怎么用
- 原文未据此给出推荐。
局限性
- 关于成人AE或银屑病患者中与抑郁、焦虑及SMI相关因素的研究有限。
- 银屑病患者中与抑郁或焦虑相关因素的观察性证据存在冲突或来自单一研究。
- AE或银屑病患者中与SMI相关因素的证据尤其有限。
- 随机对照试验的随访有限,因此对心理健康的长期影响尚不清楚。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Evidence suggests an association between atopic eczema (AE) or psoriasis and mental illness; however, the factors associated with mental illness are unclear. OBJECTIVES: To synthesize and evaluate all available evidence on factors associated with depression, anxiety and severe mental illness (SMI) among adults with AE or psoriasis. METHODS: We searched electronic databases, grey literature databases and clinical trial registries from inception to February 2022 for studies of adults with AE or psoriasis. Eligible studies included randomized controlled trials (RCTs), cohort, cross-sectional or case-control studies where effect estimates of factors associated with depression, anxiety or SMI were reported. We did not apply language or geographical restrictions. We assessed risk of bias using the Quality in Prognosis Studies tool. We synthesized results narratively, and if at least two studies were sufficiently homogeneous, we pooled effect estimates in a random effects meta-analysis. RESULTS: We included 21 studies (11 observational, 10 RCTs). No observational studies in AE fulfilled our eligibility criteria. Observational studies in people with psoriasis mostly investigated factors associated with depression or anxiety - one cross-sectional study investigated factors associated with schizophrenia. Pooled effect estimates suggest that female sex and psoriatic arthritis were associated with depression [female sex: odds ratio (OR) 1.62, 95% confidence interval (CI) 1.09-2.40, 95% prediction intervals (PIs) 0.62-4.23, I2 = 24.90%, τ2 = 0.05; psoriatic arthritis: OR 2.26, 95% CI 1.56-3.25, 95% PI 0.21-24.23, I2 = 0.00%, τ2 = 0.00] and anxiety (female sex: OR 2.59, 95% CI 1.32-5.07, 95% PI 0.00-3956.27, I2 = 61.90%, τ2 = 0.22; psoriatic arthritis: OR 1.98, 95% CI 1.33-2.94, I2 = 0.00%, τ2 = 0.00). Moderate/severe psoriasis was associated with anxiety (OR 1.14, 95% CI 1.05-1.25, I2 0.00%, τ2 = 0.00), but not depression. Evidence from RCTs suggested that adults with AE or psoriasis given placebo had higher depression and anxiety scores compared with comparators given targeted treatment (e.g. biologic agents). CONCLUSIONS: Our review highlights limited existing research on factors associated with depression, anxiety and SMI in adults with AE or psoriasis. Observational evidence on factors associated with depression or anxiety in people with psoriasis was conflicting or from single studies, but some identified factors were consistent with those in the general population. Evidence on factors associated with SMIs in people with AE or psoriasis was particularly limited. Evidence from RCTs suggested that AE and psoriasis treated with placebo was associated with higher depression and anxiety scores compared with skin disease treated with targeted therapy; however, follow-up was limited. Therefore, long-term effects on mental health are unclear.
引用
- Adesanya EI, Matthewman J, Schonmann Y, et al. Factors associated with depression, anxiety and severe mental illness among adults with atopic eczema or psoriasis: a systematic review and meta-analysis. Br J Dermatol. 2023. PMID: 36745557. doi:10.1093/bjd/ljac132
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。